59 related articles for article (PubMed ID: 2324586)
21. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
[TBL] [Abstract][Full Text] [Related]
23. Experimental and clinical studies with active specific immunotherapy.
Livingston PO
Prog Clin Biol Res; 1989; 288():309-21. PubMed ID: 2654953
[TBL] [Abstract][Full Text] [Related]
24. Oncofetal antigen 5T4 expression as a prognostic factor in patients with gastric cancer.
Naganuma H; Kono K; Mori Y; Takayoshi S; Stern PL; Tasaka K; Matsumoto Y
Anticancer Res; 2002; 22(2B):1033-8. PubMed ID: 12168897
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
[TBL] [Abstract][Full Text] [Related]
26. Glycosphingolipid antigens in neural tumor cell lines and anti-glycosphingolipid antibodies in sera of patients with neural tumors.
Ariga T; Suetake K; Nakane M; Kubota M; Usuki S; Kawashima I; Yu RK
Neurosignals; 2008; 16(2-3):226-34. PubMed ID: 18253060
[TBL] [Abstract][Full Text] [Related]
27. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
[TBL] [Abstract][Full Text] [Related]
28. [Characteristics of heterologous membrane antigen (HM Ag) and humoral immune response to HM Ag in pregnant women and patients with gynecologic malignancies].
Higuchi M; Takeuchi Y; Takeuchi S
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Nov; 38(11):1964-8. PubMed ID: 3794446
[TBL] [Abstract][Full Text] [Related]
29. Clinical applications of monoclonal antibodies in gynecologic oncology.
Smith LH; Teng NN
Cancer; 1987 Oct; 60(8 Suppl):2068-74. PubMed ID: 3308066
[TBL] [Abstract][Full Text] [Related]
30. Biological distribution of oncofetal antigen-I (OFA-I) in gynecologic tumors and trophoblastic tissues.
Higuchi M; Takeuchi S
Asia Oceania J Obstet Gynaecol; 1983 Dec; 9(4):461-4. PubMed ID: 6667172
[No Abstract] [Full Text] [Related]
31. [Clinical implication of serum antibody to Thomsen-Friedenreich antigen in patients with gynecological malignancies].
Yasui T; Sakamoto Y; Ueda T; Maeda N; Shitsukawa K; Furumoto H; Mori K; Daitoh T; Irahara M; Kamada M
Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):583-7. PubMed ID: 3385276
[TBL] [Abstract][Full Text] [Related]
32. Identification of antigenic components recognized by "membrane-bound" antibodies from ovarian cancer patients.
Taylor DD; Homesley HD; Doellgast GJ
Am J Reprod Immunol (1980); 1984 Dec; 6(4):179-84. PubMed ID: 6528883
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies in gynecological oncology: facts and future.
Bosman FT
Eur J Obstet Gynecol Reprod Biol; 1985 Jun; 19(6):361-4. PubMed ID: 4018375
[No Abstract] [Full Text] [Related]
34. [New knowledge on immunology in gynecologic cancer].
Kreienberg R
Arch Gynecol Obstet; 1987; 242(1-4):215-26. PubMed ID: 3318719
[No Abstract] [Full Text] [Related]
35. [Immunology and oncology].
Mallmann P; Weitzel H
Arch Gynecol Obstet; 1995; 257(1-4):561-6. PubMed ID: 8579441
[No Abstract] [Full Text] [Related]
36. Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status.
Bellati F; Visconti V; Napoletano C; Antonilli M; Frati L; Panici PB; Nuti M
Curr Cancer Drug Targets; 2009 Jun; 9(4):541-65. PubMed ID: 19519321
[TBL] [Abstract][Full Text] [Related]
37. [The clinical significance of antibody against oncofetal antigen-I in patients with gynecologic tumors].
Higuchi M; Ohsawa S
Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):25-30. PubMed ID: 2324586
[TBL] [Abstract][Full Text] [Related]
38. [A study on clinical significance of oncofetal antigen-1 in gynecologic tumors].
Takahashi M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Dec; 36(12):2613-8. PubMed ID: 6520482
[TBL] [Abstract][Full Text] [Related]
39. Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man.
Irie RF; Giuliano AE; Morton DL
J Natl Cancer Inst; 1979 Aug; 63(2):367-73. PubMed ID: 88539
[TBL] [Abstract][Full Text] [Related]
40. The clinical significance of antibody against oncofetal antigen-I (anti-OFA-I) in patients with gynecologic tumors.
Higuchi M; Takahashi M; Takeuchi Y; Hando T; Takeuchi S
Asia Oceania J Obstet Gynaecol; 1986 Sep; 12(3):419-23. PubMed ID: 3778321
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
